astragli membranceus

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• allergic rhinitis [Insufficient Evidence]
• amenorrhea [Insufficient Evidence]
• anemia, chemo-related [Insufficient Evidence]
• angina [Insufficient Evidence]
• anthracycline-induced cardiotoxicity [Insufficient Evidence]
• aplastic anemia [Insufficient Evidence]
• asthma [Insufficient Evidence]
• beta-thalassemia [Insufficient Evidence]
• breast CA [Insufficient Evidence]
• cervical CA [Insufficient Evidence]
• CHF [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• cirrhosis [Insufficient Evidence]
• CKD [Insufficient Evidence]
• colorectal CA [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• diabetic nephropathy [Insufficient Evidence]
• diabetic retinopathy [Insufficient Evidence]
• diarrhea, chemo-related [Insufficient Evidence]
• fatigue, chemo-related [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• gastric CA [Insufficient Evidence]
• hearing loss [Insufficient Evidence]
• hepatitis B [Insufficient Evidence]
• HIV/AIDS [Insufficient Evidence]
• leukopenia, chemo-related [Insufficient Evidence]
• IgA nephropathy [Insufficient Evidence]
• lung CA [Insufficient Evidence]
• membranous nephropathy [Insufficient Evidence]
• menopausal sx [Insufficient Evidence]
• MI [Insufficient Evidence]
• myocarditis [Insufficient Evidence]
• nausea/vomiting, chemo-related [Insufficient Evidence]
• nephrotoxicity, chemo-related [Insufficient Evidence]
• nephrotic syndrome [Insufficient Evidence]
• obesity [Insufficient Evidence]
• post-stroke fatigue [Insufficient Evidence]
• SLE [Insufficient Evidence]
• tinnitus [Insufficient Evidence]
• URI [Insufficient Evidence]
• UTI [Insufficient Evidence]
• wound healing [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note, COVID-19

[no scientific data for COVID-19]

Info: see Herb & Supplement Remedy Use in COVID-19 Resources

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

allergic rhinitis

[Insufficient Evidence]

Dose: 160 mg PO bid; Info: stdzd to 40% polysaccharides

amenorrhea

[Insufficient Evidence]

Dose: 30 g/day PO divided bid

angina

[Insufficient Evidence]

Dose: 20 g PO tid

anthracycline-induced cardiotoxicity

[Insufficient Evidence]

Dose: 500 mg IV qd x14 days

aplastic anemia

[Insufficient Evidence]

Dose: 80-120 g IV qd x15 days; Info: given at 7-10 day intervals for at least 4mo in pts 15 yo and older

CHF

[Insufficient Evidence]

Dose: 2.25-7.5 g PO bid; Alt: 60 g IV qd

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 30 g/day PO divided bid

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 10-60 g PO qd; Alt: 40-80 g IV qd; Info: used w/ or w/o metformin

diarrhea, chemo-related

[Insufficient Evidence]

Dose: 40 g IV qd x21 days/cycle

fatigue, chemo-related

[Insufficient Evidence]

Dose: 500 mg IV 3x/wk x4wk/cycle

hearing loss

[Insufficient Evidence]

Dose: 1 g/kg/dose IV qd x10 days

membranous nephropathy

[Insufficient Evidence]

Dose: 20-90 g PO qd; Info: used w/ conventional tx

menopausal sx

[Insufficient Evidence]

Dose: 15-30 g PO qd

myocarditis

[Insufficient Evidence]

Dose: 8 g IM qd x3-4mo; Alt: 40 g IV qd x2wk

nausea/vomiting, chemo-related

[Insufficient Evidence]

Dose: 40 g IV qd x21 days/cycle

nephrotic syndrome, peds pts

[Insufficient Evidence]

Dose: 7.5 g PO bid in pts <3 yo; 10 g PO bid in pts 3-6 yo; 15 g PO bid in pts 6 yo and older

post-stroke fatigue

[Insufficient Evidence]

Dose: 2.8 g PO tid

SLE

[Insufficient Evidence]

Dose: 40 g IV qd x12 days/mo x3mo; Info: used w/ corticosteroids and cyclophosphamide 0.8 g IV qmo

tinnitus

[Insufficient Evidence]

Dose: 1 g/kg/dose IV qd x10 days

UTI

[Insufficient Evidence]

Dose: 100 mg PO bid x5 days; Info: for use in female pts 18 yo and older